➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Medtronic
Moodys
Johnson and Johnson
McKinsey

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

ESKALITH CR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Eskalith Cr patents expire, and when can generic versions of Eskalith Cr launch?

Eskalith Cr is a drug marketed by Jds Pharms and is included in one NDA.

The generic ingredient in ESKALITH CR is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.

US ANDA Litigation and Generic Entry Outlook for Eskalith Cr

A generic version of ESKALITH CR was approved as lithium carbonate by HIKMA on January 29th, 1982.

  Start Trial

Summary for ESKALITH CR
Drug patent expirations by year for ESKALITH CR
Recent Clinical Trials for ESKALITH CR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Patient-Centered Outcomes Research InstitutePhase 4
Washington University School of MedicinePhase 4
University Hospitals Cleveland Medical CenterPhase 4

See all ESKALITH CR clinical trials

US Patents and Regulatory Information for ESKALITH CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jds Pharms ESKALITH CR lithium carbonate TABLET, EXTENDED RELEASE;ORAL 018152-001 Mar 29, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
McKinsey
Colorcon
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.